Elisabet Lidbrink
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, RNA modifications and cancer, Global Cancer Incidence and Screening
Most-Cited Works
- → Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression(2012)532 cited
- → Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial(2000)342 cited
- → FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer(2012)264 cited
- → Randomized study of mammography screening — preliminary report on mortality in the stockholm trial(1991)262 cited
- → Followup after 11 years – update of mortality results in the Stockholm mammographic screening trial(1997)223 cited
- → TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial(2011)125 cited
- → Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial(2010)122 cited
- → Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial(1996)120 cited
- → Treatment Failure and Dietary Habits in Women With Breast Cancer(1993)118 cited
- → HER2 status in a population-derived breast cancer cohort: discordances during tumor progression(2010)118 cited